PARASTOP – Paracetamol with Strong Opioids. A randomized, double-blind, parallel-group non-inferiority phase III withdrawal trial of paracetamol versus placebo in conjunction with opioids for moderate to severe cancer-related pain

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515012-53-00

Acronym

PARASTOP

Enrollment

179

Registered

2024-10-29

Start date

2021-10-20

Completion date

Unknown

Last updated

2025-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic cancer disease

Brief summary

Average pain intensity

Detailed description

Patient reported opioid related side effects, Patient reported opioid related side effects, Opioid consumption Day 8 (Total amount of scheduled and on demand opioids)

Interventions

DRUGParacet 1 g tabletter

DRUGPLACEBO

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Average pain intensity	—

Secondary

Measure	Time frame
Patient reported opioid related side effects, Patient reported opioid related side effects, Opioid consumption Day 8 (Total amount of scheduled and on demand opioids)	—

Countries

Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026